RELEXXII Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Relexxii, and what generic alternatives are available?
Relexxii is a drug marketed by Osmotica Pharm Us and is included in one NDA.
The generic ingredient in RELEXXII is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Relexxii
A generic version of RELEXXII was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
Summary for RELEXXII
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in RELEXXII? | RELEXXII excipients list |
| DailyMed Link: | RELEXXII at DailyMed |
Pharmacology for RELEXXII
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
Anatomical Therapeutic Chemical (ATC) Classes for RELEXXII
US Patents and Regulatory Information for RELEXXII
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-001 | Jun 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-007 | Jun 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-004 | Jun 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-002 | Jun 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-003 | Jun 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-006 | Jun 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
